Predicted protein targets (top 1)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | FAAH | O00519 | 19/20 | 0.62 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL29022674 | 0.96 | FAAH (0.66) | FAAH | |
| SCHEMBL6758311 | 0.96 | FAAH (0.66) | FAAH | |
| SCHEMBL13637520 | 0.94 | FAAH (0.62) | FAAH | |
| SCHEMBL1422634 | 0.88 | FAAH (0.49) | FAAH | |
| SCHEMBL594716 | 0.88 | CYP17A1 (0.52) | FAAH | |
| SCHEMBL8575829 | 0.88 | KMT2A (0.63) | FAAH | |
| SCHEMBL31742266 | 0.87 | PPARA (0.57) | FAAH | |
| SCHEMBL3367342 | 0.87 | FAAH (0.49) | FAAH | |
| SCHEMBL13827423 | 0.87 | CYP17A1 (0.48) | FAAH | |
| SCHEMBL22568331 | 0.87 | LMNA (0.51) | FAAH |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | ASTRAZENECA AB (SE) | 2010-06-10 | — | — | US | disclosed |
| EP-2134687-A1 | PIPERAZINE AND PIPERIDINE MGLUR5 POTENTIATORS | AstraZeneca AB (SE) | 2009-12-23 | — | — | EP | disclosed |
| WO-2008112440-A1 | PIPERAZINE AND PIPERIDINE MGLUR5 POTENTIATORS | ASTRAZENECA AB (SE) | 2008-09-18 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20100144710-A1 | Piperazine and Piperidine MGLUR5 Potentiators | GRM5, GRM1, GRM2 | FAAH 593/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.